Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

NCT03772353 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Pyrotinib
DRUG: Letrozole
DRUG: Fulvestrant

Sponsor

Fudan University

Collaborators

[object Object]